Literature DB >> 24751813

Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment.

Antonio Drago1, Ina Giegling, Martin Schäfer, Annette M Hartmann, Bettina Konte, Marion Friedl, Alessandro Serretti, Dan Rujescu.   

Abstract

AIM: The aim of the study was to detect the genetic predictors of reseponse to haloperidol.
BACKGROUND: Haloperidol is a benchmark drug for the pharmacological treatment of schizophrenia, but the genetics of its efficacy is yet to be elucidated.
METHODS: A genome-wide association analysis was carried out in a small sample of patients treated with haloperidol (n=96) and the results were replicated in a larger sample of patients treated with second-generation antipsychotics or perphenazine (final n=169, available from the Clinical Antipsychotic Trials for Intervention Effectiveness study). The Positive and Negative Symptom Scale % score decrease was the outcome in both samples. The period of observation was restricted to 1 month in the replication sample and the most severe cases were included to best balance the replication. The quality control (QC) for the investigation and replication sample included a minor allele frequency at least 0.01, call rate at least 0.95, and Hardy-Weinberg equilibrium P at least 0.0001. The source for imputation was the 1000 Genomes Pilot+HapMap 3 dataset. In total 1 080 870 single nucleotide polymorphisms (SNPs) were available after imputation and QC in the investigation sample. After QC of real genotypes, locus-targeted imputations were restricted to windows of 10 kb on either side of the sentinel SNP in the replication sample. Sentinel SNPs were the most significant findings in the investigation sample. Analysis of variance was the test of choice, PLINK, SNPTEST, and GTOOL were used in the analysis.
RESULTS: Two SNPs (rs7912580 and rs2412459) were associated with response in both samples, respectively, located in an intergenic region between the AT-rich interactive domain 5B (ARID5B, MRF1-like) gene and rhotekin 2 (RTKN2) gene, an intronic region located in the eukaryotic translation initiation factor 2α kinase 4 (EIF2AK4) gene (P=1.358e-06 and 0.015 for the Positive and Negative Symptom Scale % total score decrease in the investigation and replication samples, respectively). The direction of association was opposite in the two samples, a finding that is sometimes reported as a flip-flop association.
CONCLUSION: Heterozygosis for the ancestral allele was associated with the best improvement in the investigation sample and with poorer outcome in the replication sample. This discrepancy can be because of differences in the replication and investigation sample including the drugs used and the severity at baseline. Nevertheless, this finding is in line with two relevant hypothesis of schizophrenia, related to alterations in the immunological system (RTKN2) and in the neurodevelopment of the central nervous system (EIF2AK4). More studies are warranted to further investigate these associations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24751813     DOI: 10.1097/FPC.0000000000000052

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  13 in total

1.  Genome-wide association analysis to predict optimal antipsychotic dosage in schizophrenia: a pilot study.

Authors:  Arthur T Koga; John Strauss; Clement Zai; Gary Remington; Vincenzo De Luca
Journal:  J Neural Transm (Vienna)       Date:  2016-01-28       Impact factor: 3.575

Review 2.  [Pharmacogenetics in psychiatry: state of the art].

Authors:  D J Müller; E J Brandl; F Degenhardt; K Domschke; H Grabe; O Gruber; J Hebebrand; W Maier; A Menke; M Riemenschneider; M Rietschel; D Rujescu; T G Schulze; L Tebartz van Elst; O Tüscher; J Deckert
Journal:  Nervenarzt       Date:  2018-03       Impact factor: 1.214

Review 3.  Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications.

Authors:  Kazunari Yoshida; Daniel J Müller
Journal:  Mol Neuropsychiatry       Date:  2018-09-26

4.  General control nonderepressible 2 deletion predisposes to asparaginase-associated pancreatitis in mice.

Authors:  Lindsey Phillipson-Weiner; Emily T Mirek; Yongping Wang; W Geoffrey McAuliffe; Ronald C Wek; Tracy G Anthony
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-03-11       Impact factor: 4.052

5.  Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.

Authors:  Zelalem Petros; Eyasu Makonnen; Eleni Aklillu
Journal:  OMICS       Date:  2017-02-16

6.  Genes involved in pruning and inflammation are enriched in a large mega-sample of patients affected by Schizophrenia and Bipolar Disorder and controls.

Authors:  Marco Calabrò; Calabrò Marco; Antonio Drago; Drago Antonio; Antonina Sidoti; Sidoti Antonina; Alessandro Serretti; Serretti Alessandro; Concetta Crisafulli; Crisafulli Concetta
Journal:  Psychiatry Res       Date:  2015-06-26       Impact factor: 3.222

7.  Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.

Authors:  Samar S M Elsheikh; Daniel J Müller; Jennie G Pouget
Journal:  Methods Mol Biol       Date:  2022

Review 8.  The promise of biological markers for treatment response in first-episode psychosis: a systematic review.

Authors:  Guillaume Fond; Marc-Antoine d'Albis; Stéphane Jamain; Ryad Tamouza; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Markus Leweke; Shôn Lewis; Phillip McGuire; Andreas Meyer-Lindenberg; Iris E Sommer; Inge Winter-van Rossum; Shitij Kapur; René S Kahn; Dan Rujescu; Marion Leboyer
Journal:  Schizophr Bull       Date:  2015-03-10       Impact factor: 9.306

Review 9.  Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis).

Authors:  Julian Banerji
Journal:  Int J Mol Med       Date:  2015-07-15       Impact factor: 4.101

Review 10.  Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review.

Authors:  Amy L Gillespie; Ruta Samanaite; Jonathan Mill; Alice Egerton; James H MacCabe
Journal:  BMC Psychiatry       Date:  2017-01-13       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.